BR112016025997A2 - compostos para tratamento de doenças e lesões oftalmológicas, uma composição farmacêutica e uma formulação oftálmica - Google Patents
compostos para tratamento de doenças e lesões oftalmológicas, uma composição farmacêutica e uma formulação oftálmicaInfo
- Publication number
- BR112016025997A2 BR112016025997A2 BR112016025997A BR112016025997A BR112016025997A2 BR 112016025997 A2 BR112016025997 A2 BR 112016025997A2 BR 112016025997 A BR112016025997 A BR 112016025997A BR 112016025997 A BR112016025997 A BR 112016025997A BR 112016025997 A2 BR112016025997 A2 BR 112016025997A2
- Authority
- BR
- Brazil
- Prior art keywords
- ophthalmic
- injuries
- compounds
- pharmaceutical composition
- treating
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 1
- 230000006378 damage Effects 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 238000009472 formulation Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14167490 | 2014-05-08 | ||
| EP14170616 | 2014-05-30 | ||
| PCT/EP2015/060166 WO2015169944A1 (en) | 2014-05-08 | 2015-05-08 | Compounds for treating ophthalmic diseases and disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BR112016025997A2 true BR112016025997A2 (pt) | 2017-08-15 |
| BR112016025997A8 BR112016025997A8 (pt) | 2021-07-06 |
Family
ID=53051826
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112016025997A BR112016025997A8 (pt) | 2014-05-08 | 2015-05-08 | compostos para tratamento de doenças e lesões oftalmológicas, uma composição farmacêutica e uma formulação oftálmica |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US11730716B2 (pt) |
| EP (1) | EP3139914B1 (pt) |
| JP (1) | JP6629840B2 (pt) |
| KR (1) | KR102312186B1 (pt) |
| CN (2) | CN106572968A (pt) |
| AU (1) | AU2015257651B2 (pt) |
| BR (1) | BR112016025997A8 (pt) |
| CA (1) | CA2947067C (pt) |
| CL (1) | CL2016002812A1 (pt) |
| ES (1) | ES2960598T3 (pt) |
| HK (1) | HK1231417A1 (pt) |
| IL (1) | IL248732B (pt) |
| MX (1) | MX2016014634A (pt) |
| NZ (1) | NZ725574A (pt) |
| PL (1) | PL3139914T3 (pt) |
| SG (1) | SG11201608835VA (pt) |
| WO (1) | WO2015169944A1 (pt) |
| ZA (1) | ZA201607260B (pt) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201112091D0 (en) | 2011-07-14 | 2011-08-31 | Gt Biolog Ltd | Bacterial strains isolated from pigs |
| GB201117313D0 (en) | 2011-10-07 | 2011-11-16 | Gt Biolog Ltd | Bacterium for use in medicine |
| GB201306536D0 (en) | 2013-04-10 | 2013-05-22 | Gt Biolog Ltd | Polypeptide and immune modulation |
| SI3065748T1 (en) | 2014-12-23 | 2018-05-31 | 4D Pharma Research Limited | Severe bacteroid tethethioomycron and its use in reducing inflammation |
| EP3400953A1 (en) | 2014-12-23 | 2018-11-14 | 4D Pharma Research Limited | Pirin polypeptide and immune modulation |
| MX2017016529A (es) | 2015-06-15 | 2018-03-12 | 4D Pharma Res Ltd | Composiciones que comprenden cepas bacterianas. |
| MA41060B1 (fr) | 2015-06-15 | 2019-11-29 | 4D Pharma Res Ltd | Compositions comprenant des souches bactériennes |
| CN108271354B (zh) | 2015-06-15 | 2022-07-29 | 4D制药研究有限公司 | 包含细菌菌株的组合物 |
| PE20180242A1 (es) | 2015-06-15 | 2018-01-31 | 4D Pharma Res Ltd | Composiciones que comprenden cepas bacterianas |
| MA41010B1 (fr) | 2015-06-15 | 2020-01-31 | 4D Pharma Res Ltd | Compositions comprenant des souches bactériennes |
| GB201520497D0 (en) | 2015-11-20 | 2016-01-06 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
| DK3209310T3 (en) | 2015-11-20 | 2018-04-16 | 4D Pharma Res Ltd | COMPOSITIONS COMPREHENSIVE BAKERY STUES |
| GB201520631D0 (en) | 2015-11-23 | 2016-01-06 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
| GB201520638D0 (en) | 2015-11-23 | 2016-01-06 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
| CA3009826A1 (en) * | 2015-12-30 | 2017-07-06 | Agios Pharmaceuticals, Inc. | Treatment of tumors incorporating mutant isocitrate dehydrogenase |
| GB201612191D0 (en) | 2016-07-13 | 2016-08-24 | 4D Pharma Plc | Compositions comprising bacterial strains |
| EA035949B1 (ru) | 2016-03-04 | 2020-09-04 | 4Д ФАРМА ПиЭлСи | Применение композиции, содержащей бактериальный штамм вида blautia hydrogenotrophica, и способ лечения или предотвращения висцеральной гиперчувствительности |
| TW201821093A (zh) | 2016-07-13 | 2018-06-16 | 英商４Ｄ製藥有限公司 | 包含細菌菌株之組合物 |
| GB201621123D0 (en) | 2016-12-12 | 2017-01-25 | 4D Pharma Plc | Compositions comprising bacterial strains |
| US20180369206A1 (en) | 2017-04-24 | 2018-12-27 | Aurigene Discovery Technologies Limited | Methods of Use for Trisubstituted Benzotriazole Derivatives as Dihydroorotate Oxygenase Inhibitors |
| TWI787272B (zh) | 2017-05-22 | 2022-12-21 | 英商4D製藥研究有限公司 | 包含細菌菌株之組合物 |
| WO2018215782A1 (en) | 2017-05-24 | 2018-11-29 | 4D Pharma Research Limited | Compositions comprising bacterial strain |
| SI3638271T1 (sl) | 2017-06-14 | 2021-01-29 | 4D Pharma Research Limited | Sestavki, ki vsebujejo bakterijske seve |
| DK3804737T3 (da) | 2017-06-14 | 2022-07-25 | 4D Pharma Res Ltd | Sammensætninger omfattende bakteriestammer |
| US20200121652A1 (en) * | 2017-06-16 | 2020-04-23 | The Doshisha | Compounds having caspase inhibitory activity, pharmaceutical agent containing said compounds and for treating or preventing corneal endothelial symptoms, disorders, or diseases, and application of said pharmaceutical agent |
| CA3067332A1 (en) | 2017-06-16 | 2018-12-20 | The Doshisha | Mtor-inhibitor-containing medicine for treating or preventing ophthalmic symptoms, disorders, or diseases, and application thereof |
| MX2020008678A (es) | 2018-02-20 | 2020-09-25 | Servier Lab | Metodos de uso para derivados de benzotriazol trisustituidos. |
| CN111163757B (zh) * | 2018-03-09 | 2022-04-19 | 帕诺泰斯制药有限公司 | 眼用制剂 |
| UA128135C2 (uk) * | 2018-03-16 | 2024-04-17 | Іммунік Аґ | Поліморфи кальцієвої солі як протизапальні, імуномодулюючі та антипроліферативні засоби |
| US10889548B2 (en) | 2018-03-26 | 2021-01-12 | Clear Creek Bio, Inc. | Compositions and methods for inhibiting dihydroorotate dehydrogenase |
| CN111638341A (zh) * | 2020-07-01 | 2020-09-08 | 山东凯歌智能机器有限公司 | 一种检测小细胞肺癌患者外周血循环肿瘤细胞pd-l1基因突变的试剂盒及检测方法 |
| KR20230116779A (ko) * | 2020-10-15 | 2023-08-04 | 아슬란 파마슈티컬스 피티이 엘티디 | 디히드로오로테이트 헤하이드로즈네이즈(dhodh) 저해제를 이용한 자가면역 질환의 치료 |
| BR112023020806A2 (pt) | 2021-04-09 | 2023-12-12 | Immunic Ag | Inibidores de dhodh deuterados |
| AR128080A1 (es) | 2021-12-23 | 2024-03-20 | Immunic Ag | Inhibidores de dhodh que contienen un bioisóstero de ácido carboxílico |
| WO2023168176A1 (en) * | 2022-03-01 | 2023-09-07 | Kiora Pharmaceuticals Gmbh | Salts of a dihydroorotate dehydrogenase (dhod) inhibitor |
| US20230286938A1 (en) * | 2022-03-09 | 2023-09-14 | Kiora Pharmaceuticals Gmbh | Polymorphs of a dihydroorotate dehydrogenase (dhod) inhibitor |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DD297328A5 (de) * | 1989-08-18 | 1992-01-09 | �������@���������k���Kk�� | 5-methyl-isoxalol-4-carbonsaeureanilide und 2 hydroxyethyliden-cyanoessigsaeureanilide zur behandlung von augenerkrankungen |
| AU2003301347A1 (en) * | 2002-10-17 | 2004-05-04 | Control Delivery Systems, Inc. | Methods for monitoring treatment of disease |
| CA2509138A1 (en) * | 2002-12-23 | 2004-07-08 | 4Sc Ag | Cycloalkene dicarboxylic acid compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents |
| WO2004056746A1 (en) * | 2002-12-23 | 2004-07-08 | 4Sc Ag | Cycloalkene dicarboxylic acid compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents |
| WO2004056747A1 (en) * | 2002-12-23 | 2004-07-08 | 4Sc Ag | Dhodh-inhibitors and method for their identification |
| WO2006022442A1 (ja) * | 2004-08-24 | 2006-03-02 | Santen Pharmaceutical Co., Ltd. | ジヒドロオロテートデヒドロゲナーゼ阻害活性を有する新規複素環アミド誘導体 |
| JP2006089485A (ja) * | 2004-08-24 | 2006-04-06 | Santen Pharmaceut Co Ltd | ジヒドロオロテートデヒドロゲナーゼ阻害活性を有する新規複素環アミド誘導体 |
| US20070082841A1 (en) | 2005-09-27 | 2007-04-12 | Aciont, Inc. | Ocular administration of immunosuppressive agents |
| ES2319596B1 (es) * | 2006-12-22 | 2010-02-08 | Laboratorios Almirall S.A. | Nuevos derivados de los acidos amino-nicotinico y amino-isonicotinico. |
| UY31272A1 (es) | 2007-08-10 | 2009-01-30 | Almirall Lab | Nuevos derivados de ácido azabifenilaminobenzoico |
| TWI530286B (zh) | 2009-05-04 | 2016-04-21 | 帕納特斯製藥格斯有限公司 | 作為抑制病毒化合物之抗發炎劑 |
| US20110021465A1 (en) * | 2009-07-23 | 2011-01-27 | U.S. Nutraceuticals, Llc D/B/A Valensa International | Synergistic composition and method of retarding and ameliorating photo induced retinal damage and cataracts while ameliorating dry eye syndrome |
| US8686048B2 (en) | 2010-05-06 | 2014-04-01 | Rhizen Pharmaceuticals Sa | Immunomodulator and anti-inflammatory compounds |
| JP6339011B2 (ja) * | 2011-06-10 | 2018-06-06 | ラムスコール インコーポレイテッド | 眼へのタンパク質の送出のための持続放出性製剤及びその調製方法 |
| MX2016013341A (es) * | 2014-04-11 | 2017-09-01 | Panoptes Pharma Gmbh | Agentes antiinflamatorios como compuestos virostaticos. |
-
2015
- 2015-05-08 JP JP2017510766A patent/JP6629840B2/ja not_active Expired - Fee Related
- 2015-05-08 CN CN201580036856.7A patent/CN106572968A/zh active Pending
- 2015-05-08 BR BR112016025997A patent/BR112016025997A8/pt not_active Application Discontinuation
- 2015-05-08 KR KR1020167033322A patent/KR102312186B1/ko active IP Right Grant
- 2015-05-08 PL PL15720340.7T patent/PL3139914T3/pl unknown
- 2015-05-08 ES ES15720340T patent/ES2960598T3/es active Active
- 2015-05-08 US US15/309,176 patent/US11730716B2/en active Active
- 2015-05-08 MX MX2016014634A patent/MX2016014634A/es unknown
- 2015-05-08 CN CN202310101659.5A patent/CN116077665A/zh active Pending
- 2015-05-08 AU AU2015257651A patent/AU2015257651B2/en active Active
- 2015-05-08 NZ NZ725574A patent/NZ725574A/en unknown
- 2015-05-08 EP EP15720340.7A patent/EP3139914B1/en active Active
- 2015-05-08 SG SG11201608835VA patent/SG11201608835VA/en unknown
- 2015-05-08 CA CA2947067A patent/CA2947067C/en active Active
- 2015-05-08 WO PCT/EP2015/060166 patent/WO2015169944A1/en active Application Filing
-
2016
- 2016-10-20 ZA ZA2016/07260A patent/ZA201607260B/en unknown
- 2016-11-03 IL IL248732A patent/IL248732B/en active IP Right Grant
- 2016-11-07 CL CL2016002812A patent/CL2016002812A1/es unknown
-
2017
- 2017-05-25 HK HK17105296.1A patent/HK1231417A1/zh unknown
-
2023
- 2023-03-23 US US18/189,010 patent/US20230285355A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2015257651B2 (en) | 2020-01-23 |
| ES2960598T3 (es) | 2024-03-05 |
| EP3139914A1 (en) | 2017-03-15 |
| IL248732B (en) | 2019-07-31 |
| ZA201607260B (en) | 2018-05-30 |
| CA2947067C (en) | 2023-02-14 |
| US11730716B2 (en) | 2023-08-22 |
| MX2016014634A (es) | 2017-04-10 |
| NZ725574A (en) | 2022-08-26 |
| WO2015169944A1 (en) | 2015-11-12 |
| EP3139914C0 (en) | 2023-07-26 |
| IL248732A0 (en) | 2017-01-31 |
| HK1231417A1 (zh) | 2017-12-22 |
| PL3139914T3 (pl) | 2023-11-27 |
| JP2017514917A (ja) | 2017-06-08 |
| JP6629840B2 (ja) | 2020-01-15 |
| KR102312186B1 (ko) | 2021-10-14 |
| CA2947067A1 (en) | 2015-11-12 |
| BR112016025997A8 (pt) | 2021-07-06 |
| KR20160147023A (ko) | 2016-12-21 |
| EP3139914B1 (en) | 2023-07-26 |
| US20230285355A1 (en) | 2023-09-14 |
| CL2016002812A1 (es) | 2017-03-17 |
| AU2015257651A1 (en) | 2016-11-10 |
| CN106572968A (zh) | 2017-04-19 |
| CN116077665A (zh) | 2023-05-09 |
| US20170071904A1 (en) | 2017-03-16 |
| SG11201608835VA (en) | 2016-11-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112016025997A2 (pt) | compostos para tratamento de doenças e lesões oftalmológicas, uma composição farmacêutica e uma formulação oftálmica | |
| HK1258588A1 (zh) | 用於治療眼科疾病的化合物和製劑 | |
| IL256085B (en) | A substituted derivative of cholanoic acid, a pharmaceutical composition comprising it and the substituted derivative for use in treatment | |
| BR112018009951A2 (pt) | fármaco oftálmico | |
| BR112016015838A2 (pt) | compostos heterocíclicos aromáticos, composição farmacêutica compreendendo os referidos compostos e produto de combinação | |
| GB201913962D0 (en) | Ophthalmic drug compositions | |
| DK3253382T3 (da) | Farmaceutiske sammensætninger til kombinationsterapi | |
| CL2016002164A1 (es) | Composición agroquímica para el tratamiento de follaje | |
| BR112016018062A2 (pt) | compostos terapêuticos, composição farmacêutica e usos | |
| BR112016022062A2 (pt) | Combinação, composição farmacêutica, uso de uma combinação ou de uma composição farmacêutica, e, produto farmacêutico | |
| PL3452075T3 (pl) | Oftalmiczna kompozycja farmaceutyczna | |
| BR112016025876A2 (pt) | composição, processos para preparar uma microcápsula e uma forma de dosagem unitária, forma de dosagem unitária, microcápsula, produto, uso de uma composição, e, método para tratar uma condição associada à vitamina k1 ou k2 | |
| DK3348260T3 (da) | Farmaceutisk tramadol-sammensætning til oftalmisk anvendelse | |
| DK3554534T3 (da) | Farmaceutisk sammensætning omfattende insulin | |
| EP3156055A4 (en) | Pharmaceutical composition for preventing or treating muscular weakness-related diseases, containing butylpyridinium or derivative thereof | |
| EP3192875A4 (en) | Sustained-release pharmaceutical composition for treating and preventing ophthalmic diseases | |
| BR112017013012A2 (pt) | compostos de indenil, composições farmacêuticas e usos médicos destes | |
| SG11201705194XA (en) | Pharmaceutical composition for treating diabetes | |
| ZA201607729B (en) | Pharmaceutical compositions comprising danirixin for treating infectious diseases | |
| EP3275450A4 (en) | Pharmaceutical composition for preventing or treating inflammatory diseases, containinglactococcus chungangensis | |
| EP3375443A4 (en) | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF RESPIRATORY DISEASES | |
| SG10201912046VA (en) | Pharmaceutical composition for preventing or treating regulatory t cell-mediated diseases | |
| IL280389A (en) | Bile acid receptor modulators conjugated to G.1 protein and methods of using them | |
| DK3313370T3 (da) | Oftalmologisk farmaceutisk sammensætning | |
| IL256919A (en) | Pharmaceutical compositions useful for the treatment of tissue damage |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] | ||
| B09T | Decision of refusal: decision cancelled [chapter 9.2.1 patent gazette] |
Free format text: ANULADA A PUBLICACAO CODIGO 9.2 NA RPI NO 2733 DE 23/05/2023 POR TER SIDO INDEVIDA. |
|
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] |